-- Company is on track to reportpreliminary results from setmelanotide Phase 2 trial in Prader-Willi syndrome in fourth quarter of 2025 -- -- German observational study showed setmelanotide therapy ...
-- Preliminary unaudited net revenues from global sales of IMCIVREE ® (setmelanotide) of approximately $42 million for the fourth quarter of 2024 and approximately $130 million for the full year of ...
--Rhythm Pharmaceuticals, Inc., a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback